PracticeUpdate Oncology Best of 2018

When PNH is part of the picture, make Soliris ® (eculizumab rmc ) part of the treatment * 1,2 • PNH and aplastic anaemia (AA) frequently coexist 3 • Both diseases require distinct clinical management approaches 2 • Soliris ® targets the complement-mediated haemolysis of PNH 2 • In patients with haemolytic PNH-AA treat with Soliris ® * 1,2

*Soliris ® is indicated for the treatment of patients with Paroxysmal Nocturnal Haemoglobinuria to reduce haemolysis.

PNH: Paroxysmal Nocturnal Haemoglobinuria. References: 1. Choi CW, et al. Blood Research. 2017;52(3):207-211. 2. De Latour PR, et al. Hematology. 2016;90-98. 3. Schrezenmeier H, et al. Haematologica. 2014;99:922-929. © 2018 Alexion Pharmaceuticals Australasia Pty Limited. All rights reserved. Alexion Pharmaceuticals Australasia Pty Limited. ACN 132 343 036. Suite 401, Level 4, Building A, 20 Rodborough Rd, Frenchs Forest, NSW 2086 Australia. October 2018. AU/SOL-P/18/0033